Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7162202 | 0.86 | MEN1 (0.38) | MEN1TSHRKMT2A | |
| SCHEMBL4921819 | 0.80 | MEN1 (0.43) | MEN1TSHRKMT2A | |
| SCHEMBL4914142 | 0.80 | MEN1 (0.43) | MEN1TSHRKMT2A | |
| SCHEMBL13113200 | 0.70 | MEN1 (0.57) | MEN1TSHRKMT2A | |
| Hydrochloric Acid SCHEMBL15819856 | 0.66 | MEN1 (0.63) | MEN1TSHRKMT2A | |
| Hydrochloric Acid SCHEMBL17255832 | 0.66 | MEN1 (0.63) | MEN1TSHRKMT2A | |
| SCHEMBL2640238 | 0.63 | TERT (0.31) | MEN1TSHRKMT2A | |
| SCHEMBL4768225 | 0.63 | MEN1 (0.30) | MEN1TSHRKMT2A | |
| SCHEMBL2640272 | 0.63 | TERT (0.31) | MEN1TSHRKMT2A | |
| SCHEMBL232820 | 0.63 | MEN1 (0.65) | MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877470-B1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9371322-B2 | Bicyclic aza-amides for treatment of psychiatric disorders | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-06-21 | — | — | US | disclosed |
| US-20150183786-A1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESSELSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-07-02 | — | — | US | disclosed |
| EP-2877470-A1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014015993-A1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-01-30 | — | — | WO | disclosed |
| EP-2690102-A1 | Bicyclic aza-amides for treatment of psychiatric disorders | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183786-A1 | BICYCLIC AZA-AMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS | BDNF, MAOA, HDAC10 | MEN1 4520/4885TSHR 2784/4885KMT2A 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.